Author

Meghri Katerji

National Institutes of HealthORCID 0009-0006-2263-9544Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Carolyn C. WoodroofeiD· 2 shared Eric LindbergiD· 2 shared John BrognardiD· 2 shared Maxine R. RubiniD· 2 shared Rolf E. SwensoniD· 2 shared Amy E. JamesiD· 1 shared Amy Funk· 1 shared Amy L. FunkiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Carolyn C. WoodroofeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 20, 2026

A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers

Meghri Katerji, Kailey N. Jackett, Maxine R. Rubin…·John Brognard

This study identifies compound #63 as a potent LZK inhibitor that suppresses tumor growth and enhances EGFR and PI3K pathway blockade in HNSCC and ESCC.

DOI 10.64898/2026.10.19.760245

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyScience SignalingPeer-reviewedFeb 11, 2025

Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth

Amy L. Funk, Meghri Katerji, Marwa M. Afifi…·John Brognard

This study identifies LZK as a therapeutic target in HNSCC by showing its regulation of c-MYC and GOF p53, and demonstrates PROTAC-mediated degradation as a potential treatment.

12 citations

humanbulk RNA-seq

𝕏 PostBluesky